Hans C Leier Selected Research

cannabigerolic acid

1/2022

Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hans C Leier Research Topics

Disease

9	COVID-19 02/2022 - 07/2020
6	Infections 03/2022 - 01/2021
1	Breakthrough Infections 01/2022
1	Severe Acute Respiratory Syndrome 01/2022
1	Reinfection 01/2021
1	Tuberculosis (Tuberculoses) 01/2021
1	Vesicular Stomatitis 01/2021
1	Virus Diseases (Viral Diseases) 01/2021
1	Zika Virus Infection 01/2020

Drug/Important Bio-Agent (IBA)

5	VaccinesIBA 01/2022 - 01/2021
4	Neutralizing AntibodiesIBA 01/2022 - 01/2021
3	LipidsIBA 02/2022 - 01/2020
3	AntibodiesIBA 01/2022 - 07/2020
3	BNT162 VaccineIBA 04/2021 - 01/2021
2	Glycoproteins (Glycoprotein)IBA 03/2022 - 01/2021
1	Single-Domain AntibodiesIBA 03/2022
1	AntigensIBA 01/2022
1	CannabinoidsIBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	Immune Sera (Antisera)IBA 01/2022
1	cannabigerolic acidIBA 01/2022
1	cannabidiolic acidIBA 01/2022
1	SARS-CoV-2 spike proteinIBA 01/2022
1	COVID-19 VaccinesIBA 04/2021
1	SphingomyelinsIBA 01/2021
1	GlycosphingolipidsIBA 01/2021
1	Biological ProductsIBA 07/2020
1	CeramidesIBA 01/2020
1	SphingolipidsIBA 01/2020

Therapy/Procedure

2	Therapeutics 01/2021 - 07/2020